Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS

Current Report · Items 1.01, 7.01, 9.01 · 8-K

Strata Critical Medical, Inc.

SRTANASDAQEQUITYCurrent

Entry into a Material Definitive Agreement · Regulation FD Disclosure

Item 1.01. Entry into a Material Definitive Agreement. The Credit Agreement On January 30, 2026 (the “Closing Date”), Strata Critical Medical, Inc. (the “Company”), Strata Critical, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Critical”), Trinity Air Medical, LLC, an Arizona limited liability company and wholly owned subsidiary of Critical (“Trinity Air”), Keystone Per…

Filed Feb 5, 2026Accepted Feb 5, 2026, 9:09 AM ESTCIK 1779128Accession 0001104659-26-010689
Share

Company context

Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery. Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.

Current securities

Historical securities (6)

Recent company filings

  1. 144 filingOct 2, 2026
  2. 4 filingSep 10, 2026
  3. 4 filingSep 10, 2026
  4. SCHEDULE 13G/A - filed by Steele ExpCo Holdings, LLC regarding Strata Critical Medical, Inc.Aug 20, 2026
  5. 4 filingAug 13, 2026

Disclosure sections

Items 1.01, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry into a Material Definitive Agreement. The Credit Agreement On January 30, 2026 (the “Closing Date”), Strata Critical Medical, Inc. (the “Company”), Strata Critical, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Critical”), Trinity Air Medical, LLC, an Arizona limited liability company and wholly owned subsidiary of Critical (“Trinity Air”), Keystone Perfusion Services, LLC, a Pennsylvania limited liability company and wholly owned subsidiary of Critical (“Keystone”; together with Trinity Air and any other person that becomes party thereto as a Borrower, collectively, the “Borrowers”), entered into a Credit Agreement (the “Credit Agreement”) among the Borrowers, the Company and Critical, JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), the other Loan Parties thereto, and the Lenders thereto. Capitalized terms used but not otherwise defined in this Current Report on Form 8-K (this “Current Report”) shall have the meanings ascribed to them in the Credit Agreement. The Borrowers, the Company and Critical are referred to collectively as the “Loan Parties.” The Credit Agreement provides for secured, asset-based revolving credit loans in an aggregate principal amount of up to $30.0 million (the “ABL Facility”). Subject to the conditions set forth in the Credit Agreement, the ABL Facility may be increased by up to an aggregate of $20.0 million. Under the Credit Agreement, the ABL Facility is guaranteed by the Company and Critical and is secured by perfected, first priority liens on personal property of the Loan Parties pursuant to the Pledge and Security Agreement, dated January 30, 2026 (the “Security Agreement”), executed by the Loan Parties for the benefit of the secured parties under the Credit Agreement and other Loan Documents, which is discussed in more detail below. The ABL Facility will mature on January 30, 2029 (the “Maturity Date”). Interest shall accrue at one of the following rates to be selected by Trinity (as the Borrower Representative), in its discretion: (i) a fixed rate of interest based on the Adjusted Term SOFR Rate (for interest periods of 1, 3 or 6 months) plus a 2.00% margin; or (ii) a floating rate of interest based on the Term SOFR Reference Rate for a one-month period, as adjusted on the first Business Day of each month plus a 2.00% margin. The Borrowers are required to pay a commitment fee which will accrue at 0.25% per annum on the unused portion of the ABL Facility and be payable on the first Business Day of each calendar month. Subject to the terms and conditions of the Credit Agreement, the Borrowers may also request the issuance of Letters of Credit pursuant to the ABL Facility. Letters of Credit issued under the ABL Facility accrue customary fees and generally must expire no later than five Business Days prior to the Maturity Date. The ABL Facility will be used for working capital and for other general organizational purposes. The Credit Agreement includes customary representations and warranties, affirmative and negative covenants, and events of default for credit agreements of its type and size. Affirmative covenants include, without limitation, requirements of the Company and its subsidiaries to maintain their legal existence and governmental approvals, delivery of certain financial reports, and compliance with laws and regulations. Negative covenants include, without limitation, restrictions on indebtedness, liens, mergers and other fundamental changes, investments and guarantees, asset sales and sale-leasebacks, speculative derivatives, restricted payments (including dividends and share purchases), and certain debt prepayments, and affiliate transactions, in each case subject to customary exceptions and baskets. The financial covenant under the Credit Agreement includes a springing minimum Fixed Charge Coverage Ratio of 1.05 to 1.00 for the trailing twelve month period then ending, which covenant is in effect when the Borrowers’ availability under the ABL Facility is less than the greater of (a) $5,000,000 and (b) 20% of the aggregate commitments of the lenders. The events of default include, without limitation, payment defaults, non-payment defaults, inaccuracy of representations and warranties, breaches of covenants, cross default to material indebtedness, certain bankruptcy and insolvency events, unsatisfied judgments over a threshold, certain ERISA-related events, violations of certain laws and regulations, and a change of control of the Company. Under the Credit Agreement, upon an event of default, the lenders may, among other rights, terminate their lending commitments, accelerate the Company’s obligations, require cash collateralization of letter of credit exposure, and exercise certain remedies with respect to the Collateral. The Security Agreement On the Closing Date, the Loan Parties (collectively with any additional entities that may become parties thereto, the “Grantors”) entered into the Security Agreement with the Administrative Agent. The Security Agreement establishes a security interest in substantially all of the personal property and assets of the Grantors and secures the prompt and complete payment and performance of the Grantors’ obligations under the Credit Agreement, the Security Agreement and the other Loan Documents. In connection with the execution of the Security Agreement, the Grantors also executed other ancillary loan documents customary for transactions of this type. The descriptions of the Credit Agreement and the Security Agreement in this Current Report are summaries, do not purport to be complete, and are qualified in their entirety by reference to the complete text of each agreement, which are filed as Exhibits 10.1 and 10.2 to this Current Report, respectively, and are incorporated herein by reference. The representations and warranties of the Company and its subsidiaries in the Credit Agreement and the Security Agreement were made only for purposes of that agreement and as of their specific dates and were solely for the benefit of the lenders party thereto. The Credit Agreement and the Security Agreement are contractual documents that establish and govern the legal relations among the parties thereto and are not intended to be a source of factual, business, or operational information about the Company and its subsidiaries. The representations and warranties made by the Company and its subsidiaries in the Credit Agreement and the Security Agreement may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Accordingly, investors and security holders should not rely on such representations and warranties as characterizations of the actual state of facts or circumstances.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 5, 2026, the Company issued a press release announcing the transactions contemplated by the Credit Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01, including the corresponding Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) tm265039d1_ex99-1.htm

EX-99.1 4 tm265039d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution $30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered New York, Feb 5, 2026 -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”). “This facility will improve Strata’s capital efficiency, enabling deployment of more cash towards attractive acquisition opportunities,” said Amir Cohen, Strata’s Chief Accounting and Integration Officer. “By leaving our owned aircraft fleet unencumbered, we are maintaining significant optionality for additional …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.